3-CAF Stats & Data

3‑CAF is a positional isomer of the neurotoxic para‑chloroamphetamine (PCA); animal literature on PCA shows profound, long‑lasting serotonergic depletion, hence caution is warranted when experimenting with any chloro‑substituted amphetamine despite sparse human data on 3‑CAF. Human use reports for 3‑CAF are scarce; subjective effects are described as ‘MDMA‑lite’ empathy plus typical amphetamine stimulation with relatively clean headspace. Because of monoamine release, hyperthermia, jaw clenching/bruxism, tachycardia and insomnia are common at higher doses; plan cool‑down breaks and avoid hot, crowded venues. Hydration should be moderate and include electrolytes (e.g., ~250–500 mL per hour while dancing, less at rest); over‑hydration can cause hyponatremia—sip rather than chug and include salts. Due to overlapping serotonergic mechanisms, combinations with MAOIs, DXM, tramadol, lithium, triptans, St John’s wort, 5‑HTP or other serotonergic releasers greatly increase serotonin syndrome risk; stop use and seek medical help if clonus, agitation, hyperthermia, or confusion occur. Many amphetamines (and MDMA) are CYP2D6 substrates; potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) may increase exposure and side‑effects—dose conservatively and avoid redosing. Reagent tests cannot reliably distinguish positional isomers; GC/MS‑based drug checking is strongly recommended to exclude para‑chloroamphetamines (PCA/4‑CMA) which have been reported in the market and are strongly serotonergic‑neurotoxic. Space sessions by at least 4 weeks to limit tolerance and potential serotonergic stress; avoid multi‑day binges and sleep deprivation. Always weigh doses on a 0.001 g (milligram) scale; consider an initial 1–2 mg allergy test due to unknown individual sensitivity. Avoid driving/heavy machinery during effects and for several hours after due to residual stimulation and sleep loss.